| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
We found expansion of memory-like NK cells in peripheral blood of chronic myeloid leukemia and Ph-positive acute lymphoblastic leukemia patients treated with dasatinib, and revealed that cytomegalovirus reactivation plays an important role in lymphocytosis observed in these patients. Furthermore, increases in PD-1-expressing CD56-negative NK cells were noted in these patients. Cytotoxic activity of these PD-1-expressing NK cells were enhanced by PD-1 blockade with nivolumab. In a mouse model using a colon cancer cell line, CT26, combination therapy with dasatinib and anti-PD-L1 antibody did not show any synergistic effect.
|
